Premium
THE ADDITION AT DAY 9 OF HD‐MTX TO THE (DA)‐EPOCH SCHEME WITH OR WITHOUT RITUXIMAB IS AN EFFECTIVE REGIMEN IN UNTREATED ADVANCED STAGE HIGH RISK LYMPHOMA: A FEASIBILITY STUDY
Author(s) -
Farina G.,
Iaccarino S.,
Troiano M.,
Iovine M.,
Vigliotti M.,
Attingenti E.,
Camera A.,
Frigeri F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.117_2631
Subject(s) - medicine , rituximab , regimen , lymphoma , epoch (astronomy) , oncology , gastroenterology , diffuse large b cell lymphoma , surgery , stars , physics , astronomy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom